Navigation Links
AIDS Vaccine Advocacy Coalition Calls for AIDS Vaccine Field to Work Together to Analyze STEP Study Data and Determine Best Course to Move Forward
Date:11/7/2007

Safety of Trial Volunteers Must Remain Paramount Concern

SEATTLE, Nov. 7 /PRNewswire-USNewswire/ -- The AIDS Vaccine Advocacy Coalition (AVAC) released the following statement today from Executive Director Mitchell Warren in response to the release of new data from the STEP AIDS vaccine study by Merck & Co., the US National Institute for Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network (HVTN) at a public forum at the HVTN meeting today.

The data from the STEP study released today confirm that the vaccine was not effective at either preventing infection in male volunteers or at reducing viral loads in male vaccine recipients who became infected with HIV during the trial. In addition, the data suggest that the vaccine may have made some volunteers more susceptible to acquiring HIV infection. The vaccine itself does not cause HIV. This trend was specifically observed among male volunteers who had high titers of antibody to adenovirus, the cold virus that was used, in a disabled form, in the MRK-Ad5 vaccine candidate.

"These data are deeply disappointing and troubling, and raise more questions than answers for the field of AIDS vaccine. Today's discussion of the data underscores the leadership and transparency that Merck, NIAID, and HVTN continue to show in this complex and challenging time. What is clear is that the field must continue to work on this challenge and on the larger goal of finding a safe and effective AIDS vaccine.

"As much as we would like to see a clear answer in these results to whether or not the vaccine made some volunteers more susceptible to HIV infection, the reality is that there is still significant confusion about the underlying explanation for the observed effect.

"As we move forward, the work of analyzing and interpreting the data from the STEP study, and from the companion Phambili study in South Africa, will become even more difficult and even more important.

"In the
'/>"/>

SOURCE AIDS Vaccine Advocacy Coalition
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
6. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
7. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
8. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015  Web Industries, Inc., a leading provider ... Medical Device, Advanced Composites, Consumer Products, and Wire ... Medical Specialties Preferred Converter by 3M,s Medical Specialties ... to streamline their supply chains by using Web ... materials, intermediate converting services, and contract manufacturing and ...
(Date:3/3/2015)... , March 3, 2015  AT&T 1 ... today announced that  AT&T  is the connectivity provider for ... was designed to help provide peace of mind to ... the freedom to live active lives with the confidence ... need it. The AT&T network 2 helps power ...
(Date:3/3/2015)... 3, 2015  Cyberonics, Inc. (NASDAQ: CYBX ... treatment and management of epilepsy, today announced it will ... March 11, 2015, in Miami . ... Chief Executive Officer, will speak at 1:05 PM Eastern ... chat format, and no formal materials will be presented.  ...
Breaking Medicine Technology:Web Industries Receives 3M Preferred Converter Status 2AT&T Providing Connectivity for Philips GoSafe Mobile Medical Alert System, Empowering United States Seniors to be Connected to Emergency Care On-the-Go 2AT&T Providing Connectivity for Philips GoSafe Mobile Medical Alert System, Empowering United States Seniors to be Connected to Emergency Care On-the-Go 3AT&T Providing Connectivity for Philips GoSafe Mobile Medical Alert System, Empowering United States Seniors to be Connected to Emergency Care On-the-Go 4
... Data presented at AACR 2008, SAN DIEGO, ... owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq,and ... demonstrating that,the Company,s experimental drug candidate, brostallicin, killed ... status. The study, conducted,by Cristina Geroni, Ph.D., et ...
... Inc.,(Nasdaq: MITI ), a biopharmaceutical company developing ... autoimmune diseases, today,presented at the Annual Meeting of ... Diego, CA, preclinical data of two new human ... of acute myelogenous,leukaemia (AML) and melanoma (1). BiTE ...
Cached Medicine Technology:Preclinical Study Shows CTI's Brostallicin's Cancer-Killing Ability Based on Genetic Profiling 2Preclinical Study Shows CTI's Brostallicin's Cancer-Killing Ability Based on Genetic Profiling 3Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma 2Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma 3Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma 4Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma 5
(Date:3/3/2015)... York (PRWEB) March 03, 2015 ... used to market the atypical antipsychotic medication continue ... According to court documents, the South Carolina Supreme ... that Johnson & Johnson’s Janssen Pharmaceuticals unit had ... risks. However, while the Court’s February 25th decision ...
(Date:3/3/2015)... Longtime parent visionary and inspiring new father, Lucas ... for a candid interview on the surrogacy process in ... revelation of his magical surrogacy journey — detailing the ... the birth of his precious twin girls. , ... Founder of CARE stated, “We are committed to maintaining ...
(Date:3/3/2015)... Man, Woman & Student of the Year ... and ensure access to treatments for blood cancer patients, ... their families. Through this annual national ten-week campaign, individuals ... a world without blood cancers. The national titles will ... to be announced this summer. To date, these dedicated ...
(Date:3/3/2015)... SC (PRWEB) March 03, 2015 The ... the public’s expectation of excellence in care and safe ... the position of the RNS that biologic infusions are ... under the direct supervision of a registered nurse (RN), ... reactions, including anaphylaxis can occur in patients receiving these ...
(Date:3/3/2015)... The human augmentation market is mainly driven ... wearable augmentation sector is predicted to outpace the in-built ... years. , The eye-wear sector dominates the North ... of new products launches in the region. Furthermore, strong ... as well as the rising demand for advantageous products ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 3Health News:CARE Surrogacy Center Mexico Conducts Candid Interview with Australian Father of Twins 2Health News:CARE Surrogacy Center Mexico Conducts Candid Interview with Australian Father of Twins 3Health News:The Leukemia & Lymphoma Society’s Oregon and SW Washington Chapter Kicks Off Their Eleventh Annual Man, Woman & Student of the Year Campaign 2Health News:The Leukemia & Lymphoma Society’s Oregon and SW Washington Chapter Kicks Off Their Eleventh Annual Man, Woman & Student of the Year Campaign 3Health News:Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society 2Health News:Human Augmentation Market to Pose 43.5% CAGR Through 2020, States MarketsandMarkets in its New Research Study Now Available at MarketPublishers.com 2
... The American Association for Dental Research (AADR) has ... AADR William B. Clark Fellowship in Clinical Research. This ... Meeting & Exhibition in Washington, DC, March 3, 2010. ... Department of Periodontics, University of Texas, Health Science at ...
... ... children and we are working with our members to develop new tools to keep the ... ... International Consumer Product Health & Safety Organization’s (ICPHSO) CPSC Day in Washington, D.C. on February ...
... radiation may not be necessary for early malignancy, study ... alone offers a reasonable overall level of survival for ... new study suggests. , Traditional treatment regimens for limited ... study, researchers analyzed U.S. National Cancer Institute data on ...
... , ... ... ... ...
... ... vitamin and supplement retailer recently launched a robust health encyclopedia offering health news and ... knowledge and more. , ... Shelby Township, Mich. (PRWEB) February 19, 2010 -- eVitamins™, a leading online retailer ...
... Ecological, physiological similarities provide basis for insights, expert says, ... that dolphins suffer from diseases similar to those found ... on the effects that contaminated water and seafood have ... and their diet includes much of the same seafood ...
Cached Medicine News:Health News:JPMA Supports CPSC Chairman Tenenbaum's Continued Safety Efforts 2Health News:JPMA Supports CPSC Chairman Tenenbaum's Continued Safety Efforts 3Health News:JPMA Supports CPSC Chairman Tenenbaum's Continued Safety Efforts 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 3Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 5Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 6Health News:eVitamins Launches New Health Encyclopedia 2Health News:Dolphins May Warn of Health Risks in Humans 2
Used for stenting the urethra after hypospadias or epispadias repair and to provide post-operative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... for temporary internal drainage ... to the bladder. Supplied ... Intended for one-time use. ... advised; C-Flex® and Sof-Flex® ...
Used to introduce Cook-Cope loop and other catheters for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
Used to establish a percutaneous tract into the renal pelvis for catheter placement or stone manipulation. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: